HYL — Hyloris Pharmaceuticals SA Balance Sheet
0.000.00%
Last trade - 00:00
- €336.00m
- €307.06m
- €2.81m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | — | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.205 | 64.4 | 50.5 | 43.9 | 30.7 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.333 | 0.253 | 2.32 | 5.13 | 4.1 |
Total Other Current Assets | |||||
Total Current Assets | 3.74 | 66.6 | 54 | 50.8 | 35.3 |
Net Property, Plant And Equipment | 0.098 | 0.176 | 0.295 | 1.06 | 2.15 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 5.98 | 69.2 | 63.4 | 61.9 | 47.6 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 16.1 | 2.13 | 15 | 5.77 | 6.94 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 16.2 | 10.1 | 15.4 | 6.82 | 8.79 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -10.2 | 59.1 | 48.1 | 55 | 38.8 |
Total Liabilities & Shareholders' Equity | 5.98 | 69.2 | 63.4 | 61.9 | 47.6 |
Total Common Shares Outstanding |